Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

Breast Cancer Research and Treatment

Volumn 39, Issue 3, 1996, Pages 321-326

  Kristensen, Bent ^a   Ejlertsen, Bent ^a   Mouridsen, Henning T ^a   Andersen, Knud West ^a   Lauritzen, Jes Bruun ^b  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Adjuvant tamoxifen; Breast cancer; Femoral fractures; Postmenopause

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMUR FRACTURE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SKELETON;

EID: 0029761975     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806160     Document Type: Article

References (17)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 1992
2. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbœl I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12: 992-997, 1994
3. Love R, Barden HS, Mazess RB, Epstein S, Chappell RJ: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 154: 2585-2588, 1994
4. Fischerman K, Mouridsen HT: Danish breast cancer cooperative group (DBCG). Structure and results of the organization. Acta Oncol 27: 593-596, 1988
5. Jürgensen HJ, Frœlund C, Gustafsen J, Mosbech H, Guldhammer B, Mosbech J: Registration of diagnoses in the Danish National Registry of Patients. Methods of Information in Medicine 25: 158-164, 1986
6. Sundhedstyrelsen: Evaluering af Landspatientregisteret 1990. Sygehusstatistik II: 57, 1993
7. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, Rasmussen BB, Blichert-Toft M, Andersen KW: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 27: 699-705, 1988
8. Keeting PE, Scott RF, Colvard DS, Han IK, Spelsberg TC, Riggs BL: Lack of a direct effect of estrogen on proliferation and differentiation of normal human osteoblast-like cells. J Bone Miner Res 6: 297-304, 1991
9. Ernst M, Parker MG, Rodan GA: Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element. Mol Endo 5: 1597-1606, 1991
10. Al-Azzawi F, Hart DM, Lindsay R: Long term effect of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. BMJ 294: 1261-1262, 1987
11. 3 receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 45: 257-263, 1993
12. Speirs V, Adams ER, White MC: The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol 46: 605-613, 1993
13. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322: 802-809, 1990
14. Ellenberg SS: Surrogate endpoints. Br J Cancer 68: 457-459, 1993
15. Ryan PJ, Evans P, Blake GM, Fogelman I: The effect of vertebral collapse on spinal bone mineral density measurements in osteoporosis. Bone Miner 18: 267-272, 1992
16. Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW: Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 9: 715-724, 1994
17. Evans G, Bryant HU, Magee D, Sato M, Turner RT: The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134: 2283-2288, 1994